Esperion Therapeutics (ESPR) Scheduled to Post Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) is scheduled to announce its earnings results before the market opens on Tuesday, May 3rd. Analysts expect the company to announce earnings of ($0.95) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last announced its quarterly earnings results on Tuesday, February 22nd. The biopharmaceutical company reported ($1.77) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.32) by $0.55. The company had revenue of $15.40 million during the quarter, compared to analysts’ expectations of $14.48 million. Esperion Therapeutics’s revenue for the quarter was up 60.4% on a year-over-year basis. During the same period last year, the firm earned ($3.89) earnings per share. On average, analysts expect Esperion Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of Esperion Therapeutics stock opened at $5.20 on Tuesday. The business’s 50 day simple moving average is $4.83 and its two-hundred day simple moving average is $5.86. The stock has a market capitalization of $327.50 million, a P/E ratio of -0.54 and a beta of 0.66. Esperion Therapeutics has a one year low of $3.28 and a one year high of $28.75.

Several institutional investors and hedge funds have recently bought and sold shares of ESPR. State Street Corp boosted its position in shares of Esperion Therapeutics by 81.3% during the fourth quarter. State Street Corp now owns 1,046,377 shares of the biopharmaceutical company’s stock valued at $5,232,000 after purchasing an additional 469,096 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Esperion Therapeutics by 142.3% during the fourth quarter. Geode Capital Management LLC now owns 828,196 shares of the biopharmaceutical company’s stock valued at $4,140,000 after purchasing an additional 486,325 shares in the last quarter. Morgan Stanley boosted its position in shares of Esperion Therapeutics by 16.9% during the third quarter. Morgan Stanley now owns 451,824 shares of the biopharmaceutical company’s stock valued at $5,444,000 after purchasing an additional 65,309 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its position in shares of Esperion Therapeutics by 2,010.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 290,300 shares of the biopharmaceutical company’s stock valued at $1,452,000 after purchasing an additional 276,543 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Esperion Therapeutics by 942.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 287,269 shares of the biopharmaceutical company’s stock valued at $1,437,000 after purchasing an additional 259,716 shares in the last quarter.

A number of brokerages have commented on ESPR. Northland Securities decreased their price target on Esperion Therapeutics from $10.00 to $5.00 in a research note on Wednesday, January 12th. HC Wainwright began coverage on Esperion Therapeutics in a research note on Thursday, March 10th. They issued a “buy” rating and a $22.00 price target on the stock. StockNews.com began coverage on Esperion Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, Credit Suisse Group decreased their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Friday, January 14th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and an average target price of $27.50.

About Esperion Therapeutics (Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Featured Stories